Sagent Pharmaceuticals, a leading U.S. pharmaceutical provider, and China-based Qilu Pharmaceutical have entered a strategic partnership to commercialize a portfolio of complex injectable medicines in the U.S. market. Under the agreement, Sagent will hold exclusive rights to market select injectable products developed by Qilu, which target high-impact therapeutic areas and aim to meet unmet patient needs.
The combined addressable market for these injectables is estimated at over $4.5 billion, highlighting significant demand across multiple treatment areas. The collaboration focuses on improving patient access, reducing treatment costs, and enhancing supply chain resilience for critical medications in the U.S.
Dr. Vishy Chebrol, CEO of Sagent, emphasized that the partnership aligns with the company’s goal to build a diverse and robust pharmaceutical portfolio, bringing essential therapies to patients in need. Hanchang Zhang, Vice President of Qilu, expressed enthusiasm about combining Qilu’s manufacturing expertise with Sagent’s commercial strengths to improve medicine availability and reliability.
This alliance marks a key step toward expanding access to complex injectable therapies in the U.S. while strengthening the pharmaceutical supply chain.